Health Blueprint

Back to Longevity News

News summary

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

Source: PR Newswire • Published: 29 Oct 2026, 20:01

Summarized by Masters of Longevity from PR Newswire.

PTC posted record product revenue and advanced multiple rare-disease programs.

PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Key Takeaways
  • Sephience launch is driving record product revenue and momentum.
  • INVEST-HD enrollment is ongoing and a Type C meeting was scheduled.
  • PTC acquired ST-920 and recorded $111 million as R&D expense.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickMelatonin and Heart Failure: What the Evidence Actually ShowsA 2025 study linked melatonin use with heart failure. A 2026 analysis found no significant association. Their different designs explain why the question remains open.MoL PickFrom Metrics to Better LivingEverstride’s May 2026 Consumer Health Market Briefing shows a wellness market moving from products to systems, from tracking to guidance, and from optimization to meaning. The next winners in longevity may not be the companies that measure the most. They may be the ones that help consumers translate health data into a life they actually want to live.MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.